Dossier list

Product	Form	Strength	Indication	Therapeutic Area	Dossier Availability
Product: Alectinib NEW	Form: Hard Capsules	Strength: 150mg	Indication: Non-small Lung Cancer	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q1 2029
Product: Apixaban	Form: FC Tablets	Strength: 2.5mg, 5mg	Indication: Thromboembolic Disorders	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Available
Product: Apremilast	Form: FC Tablets	Strength: 10mg, 20mg, 30mg	Indication: Psoriasis and Psoriatic Arthritis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Avatrombopag	Form: FC Tablets	Strength: 20mg	Indication: Primary chronic immune thrombocytopenia (ITP)	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Q2 2027
Product: Binimetinib	Form: FC Tablets	Strength: 15mg, 45mg	Indication: Melanoma	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q3 2026
Product: Bosutinib	Form: FC Tablets	Strength: 100mg, 400mg, 500mg	Indication: Leukemia	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Budesonide	Form: Modified-release Capsules, hard	Strength: 3mg	Indication: Crohn´s disease	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Available
Product: Cabozantinib	Form: FC Tablets	Strength: 20mg, 40mg, 60mg	Indication: Kidney, Liver and Thyroid Cancer	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q1 2027
Product: Eliglustat	Form: Hard Capsules	Strength: 84mg	Indication: Gaucher disease	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Q1 2025
Product: Eltrombopag	Form: FC Tablets	Strength: 25mg, 50mg, 75mg	Indication: Thrombocytopenia	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Available
Product: Enzalutamide	Form: FC Tablets	Strength: 40mg, 80mg, 160mg	Indication: Prostate cancer	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q4 2026
Product: Eslicarbazepine	Form: Tablets	Strength: 200mg, 800mg	Indication: Epilepsy	Therapeutic Area: Nervous System	Dossier Availability: Available
Product: Fingolimod	Form: Hard Capsules	Strength: 0.25mg, 0.5mg	Indication: Relapsing multiple sclerosis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Ibrutinib	Form: FC Tablets	Strength: 140mg, 280mg, 420mg, 560mg	Indication: Leukemia, Lymphoma	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q4 2027
Product: Isavuconazole	Form: Hard Capsules	Strength: 100mg	Indication: Aspergillosis	Therapeutic Area: Anti-infectives for Systemic Use	Dossier Availability: Q3 2026
Product: Ivacaftor	Form: FC Tablets	Strength: 75mg, 150mg	Indication: Cystic fibrosis	Therapeutic Area: Respiratory System	Dossier Availability: Q4 2025
Product: Letermovir	Form: FC Tablets	Strength: 240mg, 480mg	Indication: Prophylaxis of Cytomegalovirus Reactivation	Therapeutic Area: Anti-infectives for Systemic Use	Dossier Availability: Q2 2027
Product: Lisdexamfetamine	Form: Hard Capsules	Strength: 20mg, 30mg, 40mg, 50mg, 60mg, 70mg	Indication: ADHD	Therapeutic Area: Nervous System	Dossier Availability: Available
Product: Macitentan	Form: FC Tablets	Strength: 10mg	Indication: Pulmonary Arterial Hypertension	Therapeutic Area: Cardiovascular System	Dossier Availability: Available
Product: Migalastat	Form: Hard Capsules	Strength: 123mg	Indication: Fabry Disease	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Q1 2028
Product: Ponatinib	Form: FC Tablets	Strength: 15mg, 30mg, 45mg	Indication: Leukemia	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q1 2026
Product: Raltegravir	Form: FC Tablets	Strength: 600mg	Indication: HIV	Therapeutic Area: Anti-infectives for Systemic Use	Dossier Availability: Available
Product: Rifaximin	Form: FC Tablets	Strength: 200mg 550 mg	Indication: Travellers' diarrhoea Hepatic Encephalopathy	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Q2 2026 Q2 2026
Product: Rivaroxaban	Form: FC Tablets	Strength: 2.5mg, 10mg, 15mg, 20mg	Indication: Thromboembolic Disorders	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Available
Product: Ruxolitinib	Form: Tablets	Strength: 5mg, 10mg, 15mg, 20mg	Indication: Myelofibrosis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Sapropterin	Form: Soluble Tablets	Strength: 100mg	Indication: Hyperphenyl- alaninaemia	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Available
Product: Tafamidis NEW	Form: Tablets	Strength: 61mg	Indication: Hereditary or wild type cardiomyopathy	Therapeutic Area: Nervous System	Dossier Availability: Q4 2026
Product: Teriflunomide	Form: FC Tablets	Strength: 7mg, 14mg	Indication: Relapsing Multiple Sclerosis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Tolvaptan	Form: Tablets	Strength: 7.5mg, 15mg, 30mg, 45mg, 60mg, 90mg	Indication: Polycystic Kidney Disease	Therapeutic Area: Cardiovascular System	Dossier Availability: Available
Product: Venetoclax NEW	Form: FC Tablets	Strength: 10mg, 50mg, 100mg	Indication: Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q4 2028

Product	Form	Strength	Indication	Therapeutic Area	Dossier Availability
Product: Alectinib NEW	Form: Hard Capsules	Strength: 150mg	Indication: Non-small Lung Cancer	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q1 2029
Product: Apixaban	Form: FC Tablets	Strength: 2.5mg, 5mg	Indication: Thromboembolic Disorders	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Available
Product: Apremilast	Form: FC Tablets	Strength: 10mg, 20mg, 30mg	Indication: Psoriasis and Psoriatic Arthritis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Avatrombopag	Form: FC Tablets	Strength: 20mg	Indication: Primary chronic immune thrombocytopenia (ITP)	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Q2 2027
Product: Binimetinib	Form: FC Tablets	Strength: 15mg, 45mg	Indication: Melanoma	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q3 2026
Product: Bosutinib	Form: FC Tablets	Strength: 100mg, 400mg, 500mg	Indication: Leukemia	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Budesonide	Form: Modified-release Capsules, hard	Strength: 3mg	Indication: Crohn´s disease	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Available
Product: Cabozantinib	Form: FC Tablets	Strength: 20mg, 40mg, 60mg	Indication: Kidney, Liver and Thyroid Cancer	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q1 2027
Product: Eliglustat	Form: Hard Capsules	Strength: 84mg	Indication: Gaucher disease	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Q1 2025
Product: Eltrombopag	Form: FC Tablets	Strength: 25mg, 50mg, 75mg	Indication: Thrombocytopenia	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Available
Product: Enzalutamide	Form: FC Tablets	Strength: 40mg, 80mg, 160mg	Indication: Prostate cancer	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q4 2026
Product: Eslicarbazepine	Form: Tablets	Strength: 200mg, 800mg	Indication: Epilepsy	Therapeutic Area: Nervous System	Dossier Availability: Available
Product: Fingolimod	Form: Hard Capsules	Strength: 0.25mg, 0.5mg	Indication: Relapsing multiple sclerosis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Ibrutinib	Form: FC Tablets	Strength: 140mg, 280mg, 420mg, 560mg	Indication: Leukemia, Lymphoma	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q4 2027
Product: Isavuconazole	Form: Hard Capsules	Strength: 100mg	Indication: Aspergillosis	Therapeutic Area: Anti-infectives for Systemic Use	Dossier Availability: Q3 2026
Product: Ivacaftor	Form: FC Tablets	Strength: 75mg, 150mg	Indication: Cystic fibrosis	Therapeutic Area: Respiratory System	Dossier Availability: Q4 2025
Product: Letermovir	Form: FC Tablets	Strength: 240mg, 480mg	Indication: Prophylaxis of Cytomegalovirus Reactivation	Therapeutic Area: Anti-infectives for Systemic Use	Dossier Availability: Q2 2027
Product: Lisdexamfetamine	Form: Hard Capsules	Strength: 20mg, 30mg, 40mg, 50mg, 60mg, 70mg	Indication: ADHD	Therapeutic Area: Nervous System	Dossier Availability: Available
Product: Macitentan	Form: FC Tablets	Strength: 10mg	Indication: Pulmonary Arterial Hypertension	Therapeutic Area: Cardiovascular System	Dossier Availability: Available
Product: Migalastat	Form: Hard Capsules	Strength: 123mg	Indication: Fabry Disease	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Q1 2028
Product: Ponatinib	Form: FC Tablets	Strength: 15mg, 30mg, 45mg	Indication: Leukemia	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q1 2026
Product: Raltegravir	Form: FC Tablets	Strength: 600mg	Indication: HIV	Therapeutic Area: Anti-infectives for Systemic Use	Dossier Availability: Available
Product: Rifaximin	Form: FC Tablets	Strength: 200mg 550 mg	Indication: Travellers' diarrhoea Hepatic Encephalopathy	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Q2 2026 Q2 2026
Product: Rivaroxaban	Form: FC Tablets	Strength: 2.5mg, 10mg, 15mg, 20mg	Indication: Thromboembolic Disorders	Therapeutic Area: Blood and Blood Forming Organs	Dossier Availability: Available
Product: Ruxolitinib	Form: Tablets	Strength: 5mg, 10mg, 15mg, 20mg	Indication: Myelofibrosis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Sapropterin	Form: Soluble Tablets	Strength: 100mg	Indication: Hyperphenyl- alaninaemia	Therapeutic Area: Alimentary Tract and Metabolism	Dossier Availability: Available
Product: Tafamidis NEW	Form: Tablets	Strength: 61mg	Indication: Hereditary or wild type cardiomyopathy	Therapeutic Area: Nervous System	Dossier Availability: Q4 2026
Product: Teriflunomide	Form: FC Tablets	Strength: 7mg, 14mg	Indication: Relapsing Multiple Sclerosis	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Available
Product: Tolvaptan	Form: Tablets	Strength: 7.5mg, 15mg, 30mg, 45mg, 60mg, 90mg	Indication: Polycystic Kidney Disease	Therapeutic Area: Cardiovascular System	Dossier Availability: Available
Product: Venetoclax NEW	Form: FC Tablets	Strength: 10mg, 50mg, 100mg	Indication: Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia	Therapeutic Area: Antineoplastic and Immunomodulating Agents	Dossier Availability: Q4 2028

Coripharma´s dossier list, available for out-licencing. This list was last updated in March 2025.

About us

Services

Sustainability

Careers

Dossier list

NEW

NEW

NEW

NEW

NEW

NEW

+354 4206700